Scinai ends PC111 arrangements, shifts focus to NanoAb and CDMO business
The Israeli biopharma will not extend its option and license deal with PinCell on preclinical candidate PC111, redirecting capital toward its NanoAb platform and CDMO operations.
SEC filing